跳至主要内容
临床试验/DRKS00013938
DRKS00013938已完成不适用

TriOptimize: A prospective non-interventional Trial on COPD patients’ health related quality of life under a fixed LAMA/LABA/ICS triple therapy and characterization of determinants of treatment adherence - TriOptimize

Chiesi GmbH0 个研究点目标入组 2,623 人开始时间: 2021年12月28日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Chiesi GmbH
入组人数
2,623

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1) Patients with moderate to severe COPD (with and without asthma).
  • 2) The doctor made the decision for a therapy with Trimbow® within the scope of its German approval, regardless of the present study.
  • 3) Patients who have had at least one COPD exacerbation within the 12 months prior to starting treatment with Trimbow®.
  • 4) Patients who are willing and able to give their written consent to the use of their pseudonymised personal data for the purposes of the present study.

排除标准

  • 1) Patients who were hospitalized for a COPD exacerbation within the last 4 weeks prior to inclusion.
  • 2) Participation in a clinical trial within the last 30 days before inclusion in the present NIS.

研究者

发起方
Chiesi GmbH

相似试验